Comtan (entacapone), a new COMT inhibitor for advanced Parkinson's disease
August 2001
Novartis is now marketing Comtan (entacapone), a new COMT inhibitor for advanced Parkinson's disease.
It's used to enhance the effectiveness of levodopa/carbidopa or levodopa/benserazide.
Comtan decreases the metabolism of levodopa...leading to more sustained levels. This smooths out the response to levodopa and reduces "wearing off" periods.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote